title: Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
abstract: OBJECTIVE
  Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network.
  
  
  METHODS
  Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF).
  
  
  RESULTS
  Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy.
  
  
  CONCLUSIONS
  MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.
authors.affiliation: Eva Hoster, Roswitha Forstpointner, Wolfgang Hiddemann, Martin H. Dreyling, and Michael Unterhalt, University Hospital Munich; Eva Hoster, University of Munich, Munich; Wolfram Klapper, University of Kiel; Christiane Pott, University Hospital Schleswig-Holstein, Kiel; Michael Hallek, Universität Köln, Köln; Stephan Stilgenbauer, University of Ulm, Ulm, Germany; Olivier Hermine, University Paris Descartes and Université Sorbonne Paris Cité; Catherine Thieblemont, Hôpital Saint Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Hanneke C. Kluin-Nelemans, University of Groningen, Groningen; Jeanette Doorduijn, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Jan Walewski and Michal Szymczyk, Maria Sklodowska-Curie Memorial Institute, Warsaw, Poland; Achiel van Hoof, A. Z. Sint Jan AV, Brugge, Belgium; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Christian H. Geisler, Rigshospitalet, Copenhagen, Denmark; and Francesco Di Raimondo, University of Catania, Italy.
authors.forename: Eva
authors.initials: E
authors.lastname: Hoster
authors.forename: Wolfram
authors.initials: W
authors.lastname: Klapper
authors.forename: Olivier
authors.initials: O
authors.lastname: Hermine
authors.forename: Hanneke C
authors.initials: HC
authors.lastname: Kluin-Nelemans
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.forename: Achiel
authors.initials: A
authors.lastname: van Hoof
authors.forename: Marek
authors.initials: M
authors.lastname: Trneny
authors.forename: Christian H
authors.initials: CH
authors.lastname: Geisler
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
authors.forename: Michal
authors.initials: M
authors.lastname: Szymczyk
authors.forename: Stephan
authors.initials: S
authors.lastname: Stilgenbauer
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.forename: Roswitha
authors.initials: R
authors.lastname: Forstpointner
authors.forename: Christiane
authors.initials: C
authors.lastname: Pott
authors.forename: Vincent
authors.initials: V
authors.lastname: Ribrag
authors.forename: Jeanette
authors.initials: J
authors.lastname: Doorduijn
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hiddemann
authors.forename: Martin H
authors.initials: MH
authors.lastname: Dreyling
authors.forename: Michael
authors.initials: M
authors.lastname: Unterhalt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D003561:Cytarabine; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone